Regeneron Pharmaceuticals (REGN) Stock
Biotech powerhouse using genetics for eye and immune treatments. Here's the price, business snapshot, and what's worth knowing about Regeneron Pharmaceuticals in August 2026.
Regeneron Pharmaceuticals (REGN) is a US-based biotechnology company known for developing monoclonal antibody therapies and using human genetics to inform drug discovery. Its leading marketed products include EYLEA for retinal disease and Dupixent (co‑developed with Sanofi) for certain inflammatory conditions — both are material revenue drivers. The firm combines laboratory platforms (VelocImmune) and the Regeneron Genetics Center to identify and advance targets across ophthalmology, immunology, oncology and rare diseases. Investors should note Regeneron’s strengths in proprietary discovery technology and a deep pipeline, balanced by typical sector risks: R&D intensity, regulatory approval uncertainty, patent and pricing pressures, and possible revenue concentration around key drugs. With a market capitalisation near $61.4bn, the stock can be volatile around trial, approval and commercial updates. This summary is educational and not financial advice; consider your risk tolerance and consult a financial adviser to determine suitability.
Why It’s Moving
REGN is moving on a steady wave of analyst optimism, but pipeline questions are keeping gains in check.
- Analysts remained broadly constructive on Regeneron, with multiple firms lifting price targets in late July and early August, reinforcing the view that the company’s core drug franchise still has room to outperform expectations.
- Sentiment was tempered by a reported termination of a Real-World Dupilumab study in chronic urticaria, which may have prompted investors to recheck how much near-term growth is tied to pipeline expansion versus existing products.
- The latest consensus data still points to a Buy-leaning view overall, but the spread between higher targets and more cautious estimates suggests investors are balancing strong fundamentals against execution risk and pipeline uncertainty.
REGN is moving on a steady wave of analyst optimism, but pipeline questions are keeping gains in check.
- Analysts remained broadly constructive on Regeneron, with multiple firms lifting price targets in late July and early August, reinforcing the view that the company’s core drug franchise still has room to outperform expectations.
- Sentiment was tempered by a reported termination of a Real-World Dupilumab study in chronic urticaria, which may have prompted investors to recheck how much near-term growth is tied to pipeline expansion versus existing products.
- The latest consensus data still points to a Buy-leaning view overall, but the spread between higher targets and more cautious estimates suggests investors are balancing strong fundamentals against execution risk and pipeline uncertainty.
When is the next earnings date for REGENERON PHARMACEUTICALS INC (REGN)?
Regeneron’s next earnings date has already been announced as July 30, 2026, before the market opens. The report will cover second-quarter 2026 financial and operating results. If you are referring to the next upcoming earnings after that release, it would typically be expected in late October 2026 for Q3 2026 based on the company’s quarterly reporting pattern.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Regeneron stock, with a target price suggesting significant potential growth.
Financial Health
Regeneron is achieving strong profits and cash flow, reflecting its robust revenue and operational efficiency.
Dividend
Regeneron Pharmaceuticals' low dividend yield of 0.45% indicates limited returns for dividend-seeking investors. If you invested $1000 you would be paid $4.50 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring REGN
US Pharma Reshoring | CDMOs & Supply Chain Stocks
The Trump administration is implementing sweeping 100% tariffs on imported brand-name drugs to force pharmaceutical companies into producing their medicines stateside. This aggressive policy shift creates a highly lucrative environment for US-based contract manufacturers and domestic healthcare supply chain operators as global drugmakers rush to reshore their operations.
Published: 4 April 2026
Explore BasketAI Drug Discovery | Biotech Investment Opportunities
NVIDIA and Eli Lilly have launched a $1 billion AI lab to revolutionize the drug discovery process. This partnership highlights a burgeoning investment opportunity in companies at the intersection of artificial intelligence and biotechnology.
Published: 13 January 2026
Explore BasketDrug Pricing Power | Major Pharma Stocks 2025
Following plans by major drugmakers to raise prices on hundreds of medications, the pharmaceutical industry is showcasing its significant pricing power. This development highlights an investment opportunity centered on established pharmaceutical companies capable of translating market dominance into revenue growth.
Published: 2 January 2026
Explore BasketPharma Reshoring Explained | Manufacturing Investment
Major pharmaceutical firms have signed agreements with the U.S. government to lower drug prices in exchange for tariff exemptions and other concessions. This move is expected to drive over $150 billion in new domestic R&D and manufacturing investments, creating opportunities for U.S.-based life sciences and industrial supply chain companies.
Published: 21 December 2025
Explore BasketCancer Therapies: What's Next After 100% Response Rate
Regeneron's announcement of a 100% response rate for its new lymphoma therapy highlights a major advancement in cancer treatment. This breakthrough creates an investment opportunity centered on companies pioneering next-generation immuno-oncology drugs, particularly those developing bispecific antibodies and other innovative platforms.
Published: 7 December 2025
Explore BasketUK-US Pharma Trade Deal | Tariff-Free Market Access
A new trade deal eliminates tariffs on pharmaceuticals between the UK and the US, strengthening transatlantic trade. This creates a powerful tailwind for pharmaceutical companies in both countries, potentially boosting exports, innovation, and profitability.
Published: 2 December 2025
Explore BasketPharma Stocks: Could Pipeline Power Drive Growth?
Pharmaceutical giant Roche boosted its earnings outlook, fueled by strong sales of its innovative cancer, immunology, and diagnostic products. This success highlights a broader investment opportunity in leading drugmakers with powerful research and development engines poised for growth.
Published: 23 October 2025
Explore BasketObesity Treatment (Pharma Giants vs Biotech Firms)
Novo Nordisk's major restructuring, driven by intense competition from Eli Lilly, highlights the high-stakes battle in the weight-loss drug market. This theme focuses on other pharmaceutical companies that could benefit from this rivalry, either as innovators with next-generation treatments or as potential acquisition targets.
Published: 10 September 2025
Explore BasketPharma's Pricing Pressure
In response to a presidential ultimatum for 17 drug makers to slash U.S. prices, the pharmaceutical industry faces a major regulatory challenge. This event creates a potential investment opportunity in companies positioned to gain from the pricing disruption, including generic manufacturers.
Published: 3 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Strong product drivers
EYLEA and Dupixent are significant revenue sources and shape near-term cashflow, though sales can be sensitive to competition and reimbursement changes.
Genetics-driven R&D
Regeneron’s genetics and VelocImmune platforms can accelerate target discovery and bespoke antibodies, offering scientific optionality while R&D outcomes remain uncertain.
Regulatory sensitivity
Product approvals, label changes and pricing decisions across markets materially affect valuation; investors should expect updates to move the share price.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
